

**Arbeiten**  
**aus der Psychiatrischen Klinik der Universität München**  
**2013**

Summe IF 2013: 646.261

Anzahl IF-Arbeiten 2013: 155

1. **Aberg KA, Liu Y, Bukszár J, Mcclay JL, Khachane AN, Andreassen OA, Blackwood D, Corvin A, Djurovic S, Gurling H, Ophoff R, Pato CN, Pato MT, Riley B, Webb T, Kendler K, O'Donovan M, Craddock N, Kirov G, Owen M, Rujescu D, St Clair D, Werge T, Hultman CM, Delisi LE, Sullivan P, van den Oord EJ**  
A comprehensive family-based replication study of schizophrenia genes.  
JAMA Psychiatry 2013; 70: 573-81. IF 13.747
2. **Aichert DS, Derntl B, Wöstmann NM, Groß JK, Dehning S, Cerovecki A, Möller H-J, Habel U, Riedel M, Ettinger U**  
Intact emotion-cognition interaction in schizophrenia patients and first-degree relatives: evidence from an emotional antisaccade task.  
Brain Cogn 2013; 82: 329-336. IF 2.683
3. **Aichmüller C, Soyka M**  
Stationäre Therapie Suchtkranker mit komorbiden Störungen.  
Suchtmed 2013; 15: 21-32. IF -
4. **Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Meyer U, Müller N, Maes M**  
Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia.  
Progr Neuro-Psychopharmacol & Biol Psychiat 2013; 42: 1-4. IF 4.025
5. **Anderson-Schmidt H, Adler L, Aly C, Anghelescu I-G, Bauer M, Baumgärtner J, Becker J, Bianco R, Becker T, Bitter C, Bönsch D, Buckow K, Budde M, Bührig M, Deckert J, Demiroglu SY, Dietrich D, Dümpelmann M, Engelhardt U, Fallgatter AJ, Feldhaus D, Figge C, Folkerts H, Franz M, Gade K, Gaebel W, Grabe H-J, Gruber O, Gullatz V, Gusky L, Heilbronner U, Helbing K, Hegerl U, Heinz A, Hensch T, Hiemke C, Jäger M, Jahn-Brodmann A, Juckel G, Kandulski F, Kaschka WP, Kircher T, Koller M, Konrad C, Kornhuber J, Krause M, Krug A, Lee M, Leweke M, Lieb K, Mammes M, Meyer-Lindenberg A, Mühlbacher M,**

**Müller MJ, Nieratschker V, Nierste B, Ohle J, Pfennig A, Pieper M, Quade M, Reich-Erkelenz D, Reif A, Reitt M, Reininghaus B, Reininghaus EZ, Riemenschneider M, Rienhoff O, Roser P, Rujescu D, Schennach R, Scherk H, Schmauss M, Schneider F, Schosser A, Schott BH, Schwab SG, Schwanke J, Skrowny D, Spitzer C, Stierl S, Stöckel J, Stübner S, Thiel A, Volz H-P, von Hagen M, Walter H, Witt SH, Wobrock T, Zielasek J, Zimmermann J, Zitzelsberger A, Maier W, Falkai PG, Rietschel M, Schulze TG**

The "DGPPN-Cohort": a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients.

*Eur Arch Psychiatry Clin Neurosci* 2013; 263: 695-701. IF 3.355

6. **Andreou C, Leicht G, Popescu V, Pogarell O, Mavrogiougou P, Rujescu D, Giegling I, Zaudig M, Juckel G, Hegerl U, Mulert C**  
P300 in obsessive-compulsive disorder: source localization and the effects of treatment.  
*J Psychiatr Res* 2013; 47: 1975-83. IF 4.092
  
7. **Antypa N, Giegling I, Calati R, Schneider B, Hartmann AM, Friedl M, Konte B, Lia L, De Ronchi D, Serretti A, Rujescu D**  
MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls.  
*Eur Arch Psychiatry Clin Neurosci* 2013; 263: 393-403. IF 3.355
  
8. **Antypa N, Serretti A, Rujescu D**  
Serotonergic genes and suicide: a systematic review.  
*Eur Neuropsychopharmacol* 2013; 23: 1125-42. IF 5.395
  
9. **Apelt SM, Scherbaum N, Gözl J, Backmund M, Soyka M**  
Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.  
*Pharmacopsychiatry* 2013; 46: 94-107. IF 2.168
  
10. **Aschenbrenner S, Schale A, Weisbrod M, Laux G, Brunbauer A**  
Wiedererlangung der Fahrkompetenz.  
*Nervenheilkunde* 2013; 32: 376-380. IF -
  
11. **Baker JH, Thornton LM, Strober M, Brandt H, Crawford S, Fichter MM, Halmi KA, Johnson C, Jones I, Kaplan AS, Klump KL, Mitchell JE, Treasure J, Woodside DB, Berrettini WH, Kaye WH, Bulik CM**  
Temporal sequence of comorbid alcohol use disorder and anorexia nervosa.  
*Addict Behav* 2013; 38: 1704-1709. IF 2.441

12. **Banigan MG, Kao PF, Kozubek JA, Winslow AR, Medina J, Costa J, Schmitt A, Schneider A, Cabral H, Cagsal-Getkin O, Vanderburg CR, Delalle I**  
Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients.  
PLoS One 2013; 8: e48814. IF 3.534
13. **Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J on behalf of the Task Force on Unipolar Depressive Disorders**  
World Federation of societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders.  
World J Biol Psychiatry 2013; 14: 334-385. IF 4.225
14. **Baumgärtner G, Soyka M**  
DSM-5 – Was ändert sich für die Suchttherapie und – forschung?  
Fortschr Neurol Psychiatr 2013; 81: 648-654. IF 0.762
15. **Benninghoff J, Grunze H, Schindler C, Genius J, Schloesser RJ, van der Ven A, Dehning S, Wiltfang J, Möller H-J, Rujescu D**  
Ziprasidone – not haloperidol – induces more de-novo neurogenesis of adult neural stem cells derived from murine hippocampus.  
Pharmacopsychiatry 2013; 46: 10-15. IF 2.168
16. **Benninghoff J, Rauh W, Brantl V, Schloesser RJ, Moessner R, Möller H-J, Rujescu D**  
Cholinergic impact on neuroplasticity drives muscarinic M1 receptor mediated differentiation into neurons.  
Worl J Biol Psychiatry 2013; 14: 241-246. IF 4.225
17. **Blaschek A, Keeser D, Müller S, Koerte IK, Sebastian Schröder A, Müller-Felber W, Heinen F, Ertl-Wagner B**  
Early white matter changes in childhood multiple sclerosis: a diffusion tensor imaging study.  
AJNR Am J Neuroradiol 2013; 34: 2015-20. IF 3.675
18. **Blautzik J, Keeser D, Berman A, Paolini M, Kirsch V, Mueller S, Coates U, Reiser M, Teipel SJ, Meindl T**  
Long-term test-retest reliability of resting-state networks in healthy elderly subjects and with amnesic mild cognitive impairment patients.  
J Alzheimers Dis 2013; 34: 741-754. IF 3.612
19. **Blautzik J, Vetter C, Peres I, Gutyrchik E, Keeser D, Berman A, Kirsch V, Mueller S, Pöppel E, Reiser M, Roenneberg T, Meindl T**  
Classifying fMRI-derived resting-state connectivity patterns according to their

daily rhythmicity.  
Neuroimage 2013; 71: 298-306. IF 6.132

20. **Bogerts B, Möller-Leimkühler AM**  
Neurobiologische Ursachen und psychosoziale Bedingungen individueller Gewalt.  
Nervenarzt 2013; 84: 1329-1344. IF 0.862
21. **Borgwardt S, Koutsouleris N, Aston J, Studerus E, Smieskova R, Riechler-Rössler A, Meisenzahl EM**  
Distinguishing prodromal from first-episode psychosis using neuroanatomical single-subject pattern recognition.  
Schizophr Bull 2013; 39: 1105-14. IF 8.607
22. **Bottlender R, Strauss A, Möller H-J**  
Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 85-92. IF 3.355
23. **Brunnauer A, Laux G**  
Schizophrenie, schizotype und wahnhaftige Störungen und Fahrtauglichkeit.  
Schizophrenie 2013; 29: 27-36. IF -
24. **Brunnauer A, Laux G**  
The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review.  
J Neural Transm 2013; 120: 225-232. IF 2.871
25. **Brzózka MM, Rossner MJ**  
Deficits in trace fear memory in a mouse model of the schizophrenia risk gene TCF4.  
Behav Brain Res 2013; 237: 348-356. IF 3.391
26. **Buchheim A, Roth G, Schiepek G, Pogarell O, Karch S**  
Neurobiology of borderline personality disorder (BPD) and antisocial personality disorder (APD).  
Swiss Archives Neurology Psychiatry 2013; 164: 115-122. IF -
27. **Carballedo A, Morris D, Zill P, Fahey C, Reinhold E, Meisenzahl E, Bondy B, Gill M, Möller H-J, Frodl T**  
Brain-derived neurotrophic factor Val66Met polymorphisms and early life adversity affect hippocampal volume.  
Am J Med Genet B Neuropsychiatr Genet 2013; 162B: 183-90. IF 3.271

28. **Cerovecki A, Musil R, Klimke A, Seemüller F, Haen E, Schennach R, Kühn KU, Volz HP, Riedel M**  
Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.  
CNS Drugs 2013; 27: 545-572. IF 4.376
29. **Chiang SS, Riedel M, Schwarz M, Müller N**  
Is T-helper type 2 schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls.  
Psychiatry Clin Neurosci 2013; 67: 228-236. IF 1.620
30. **Clemm von Hohenberg C, Wigand MC, Kubicki M, Leicht G, Giegling I, Karch S, Hartmann AM, Konte B, Friedl M, Ballinger T, Eckbo R, Bouix S, Jäger L, Shenton ME, Rujescu D, Mulert C**  
CNTNAPS polymorphisms and structural brain connectivity: a diffusion-tensor imaging study.  
J Psychiatr Res 2013; 47: 1349-56. IF 4.092
31. **Costa A, la Fougère C, Pogarell, Möller H-J, Riedel M, Ettinger U**  
Impulsivity is related to striatal dopamine transporter availability in healthy males.  
Psychiatr Res 2013; 211: 251-56. IF 2.682
32. **Costa A, Riedel M, Pogarell O, Menzel-Zelnitschek F, Schwarz M, Reiser M, Möller H-J, Rubia K, Meindl T, Ettinger U**  
Methylphenidate effects on neural activity during response inhibition in healthy humans.  
Cereb Cortex 2013; 23: 1179-89. IF 8.305
33. **Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, Neale BM, Yang J, Lee SH, Evans P, Barr CL, Bellodi L, Benarroch F, Berrio GB, Bienvenue OJ, Bloch MH, Blom RM, Bruun RD, Budman CL, Camarena B, Campbell D, Cappi C, Cardona C, Cardona Silgado JC, Cath CD, Cavallini MC, Chavira DA, Chouinard S, Conti DV, Cook EH, Coric V, Cullen BA, Deforce D, Delorme R, Dion Y, Edlund CK, Egberts K, Falkai P, Fernandez TV, Gallagher PJ, Garrido H, Geller D, Girard SL, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, Haddad S, Heiman GA, Hemmings SM, Hounie AG, Illmann C, Jankovic J, Jenike MA, Kennedy JL, King RA, Kremeyer B, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Liu C, Lochner C, Lowe TL, Macciardi F, McCracken JT, McGratz LM, Mesa Restrepo SC, Moessner R, Morgan J, Muller H, Murphy DL, Naarden AL, Ochoa WC, Ophoff RA, Osiecki L, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Rauch SL, Renner TJ, Reus VI, Richter MA, Riddle MA, Robertson MM, Romero R, Rosário MC, Rosenberg D, Rouleau GA, Ruhrmann S, Ruiz-Linares A, Sampaio AS, Samuels J, Sandor P, Sheppard B, Singer HS, Smit JH, Stein DJ, Strengman E, Tischfield JA, Valencia Duarte AV, Vallada H, Van Nieuwerburgh F,**

**Veenstra-Vanderweele J, Walitza S, Wang Y, Wendland JR, Westenberg HG, Shugart YY, Miguel EC, McMahon W, Wagner M, Nicolini H, Posthuma D, Hanna GL, Heutink P, Denys D, Arnold PD, Oostra BA, Nestadt G, Freimer NB, Pauls DL, Wray NR, Stewart SE, Mathews CA, Knowles JA, Cox NJ, Scharf JM**

Partitioning the heritability of the Tourette Syndrome and obsessive compulsive disorder reveals differences in genetic architecture.

PLoS Genet 2013; 8:e1003864. IF 8.167

34. **Degenhardt F, Priebe L, Strohmaier J, Herms S, Hoffmann P, Mattheisen M, Mössner M, Nenadic I, Sauer H, Rujescu D, Maier W, Schulz TG, Rietschel M, Nöthen MM, Cichon S**  
No evidence for an involvement of copy number variation in ABCA 13 in schizophrenia, bipolar disorder, or major depressive disorder.  
Psychiatr Genet 2013; 23: 45-46. IF 2.274
35. **Dehning S, Gasperi S, Krause D, Meyer S, Reiß E, Burger M, Jacobs F, Buchheim A, Müller N, Siebeck M**  
Emotional and cognitive empathy in first-year medical students.  
ISRN Psychiatry 2013; 801530. IF -
36. **Dehning S, Gasperi S, Tesfaye M, Girma E, Meyer S, Krahl W, Riedel M, Möller H-J, Müller N, Siebeck M**  
Empathy without borders? Cross-cultural heart and mind-reading in first-year medical students.  
Ethiop J Health Sci 2013; 23: 113-122. IF -
37. **Diehl-Schmid J, Pernecky R, Koch J, Nedopil N, Kurz A**  
Guilty by suspicion? Criminal behavior in frontotemporal lobar degeneration.  
Cogn Behav Neurol 2013; 26: 73-77. IF 1.138
38. **Donohoe G, Walters J, Hargreaves A, Rose EJ, Morris DW, Fahey C, Bellini S, Cummins E, Giegling I, Hartmann AM, Möller H-J, Muglia P, Owen MJ, Gill M, O'Donovan MC, Tropea D, Rujescu D, Corvin A**  
Neuropsychological effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253.  
Genes Brain Behav 2013; 12: 203-209. IF 3.505
39. **Drago A, Giegling I, Schäfer M, Hartmann AM, Friedl M, Konte B, Möller H-J, De Ronchi D, Stassen HH, Serretti A, Rujescu D**  
AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.  
Eur Neuropsychopharmacol 2013; 23: 887-894. IF 5.395
40. **Easton AC, Lucchesi W, Lourdusamy A, Lenz B, Solati J, Golub Y, Lewczuk P, Fernandes C, Desrivieres S, Dawirs RR, Moll GH, Kornhuber J, Frank J, Hoffmann P, Soyka M, Kiefer F, GESGA Consortium,**

**Schumann G, Peter Giese K, Müller CP, Treutlein J, Cichon S, Ridinger M, Mattheisen P, Herms S, Wodarz N, Zill P, Maier W, Mössner R, Gaebel W, Dahmen N, Scherbaum N, Schmäler C, Steffens M, Lucae S, Ising M, Müller-Myshok B, Nöthen MM, Mann K, Rietschel M**

$\alpha$ CaMKII autophosphorylation controls the establishment of alcohol drinking behavior.

Neuropsychopharmacol 2013; 38: 1636-47.

Erratum in: Neuropsychopharmacol 2013; 38: 2735. IF 7.833

41. **Engl RR**  
Verhaltens- und Erlebnisinventar. Huber, Bern, 2013.
42. **Engl C, Schmidt P, Arsic M, Boucard CC, Biberacher V, Röttinger M, Etgen T, Nunnemann S, Koutsouleris N, Reiser M, Meisenzahl EM, Mühlau M**  
Brain size and white matter content of cerebrospinal tracts determine the upper cervical cord area: evidence from structural brain MRI.  
Neuroradiology 2013; 55: 963-70. IF 2.374
43. **Falkai P**  
S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen – S3-Praxisleitlinien in Psychiatrie und Psychotherapie.  
Springer, Heidelberg, 2013.
44. **Falkai P**  
Von der Therapie zur Prävention.  
Die Psychiatrie 2013; 10: 219. IF -
45. **Falkai P, Malchow B, Schmitt A**  
Neurobiological background of affective disorders.  
In: Schoepf D (ed). Psychiatric Disorders – New Frontiers in Affective Disorders.  
InTech, Croatia, 2013, S. 3-20.
46. **Falkai P, Malchow B, Wobrock T, Gruber O, Schmitt A, Honer WG, Pajonk F-G, Sun F, Cannon TD**  
The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia: a randomized controlled MRI study.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 469-473. IF 3.355
47. **Falkai P, Reich-Erkelenz D, Malchow B, Schmitt A, Majtenyi K**  
Die Gehirnentwicklung vor der psychotischen Erstmanifestation und im weiteren Verlauf der Schizophrenie.  
Fortschr Neurol Psychiatr 2013; 81: 260-264. IF 0.762

48. **Falkai P, Schmitt A**  
Untersuchung des Einflusses von Umweltfaktoren bei schweren psychischen Erkrankungen: Epigenetik als ein neuer Forschungsansatz.  
Fortschr Neurol Psychiatr 2013; 81: 367. IF 0.762
49. **Falkai P, Schmitt A**  
Verlaufsuntersuchungen in der Gruppe der Schizophrenien. Schlüssel zum Verständnis der Ätiologie.  
Nervenarzt 2013; 84: 1091-1092. IF 0.862
50. **Falkai P, Schneider F, Sauer H, Amlacher J, Schneller C, Maier W**  
Psychiatrisch-psychotherapeutische Forschung in Deutschland.  
Bestandsaufnahme und internationaler Vergleich.  
Nervenarzt 2013; 84: 1369-1381. IF 0.862
51. **Fehr C, Sommerlad D, Sander T, Anghelescu I, Dahmen N, Szegedi A, Mueller C, Zill P, Soyka M, Preuss UW**  
Association of VMAT2 gene polymorphisms with alcohol dependence.  
J Neural Transm 2013; 120: 1161-1169. IF 2.871
52. **Fichter M**  
Epidemiologie anorektischer und bulimischer Essstörungen.  
Die Psychiatrie 2013; 10: 229-333. IF -
53. **Fichter MM, Quadflieg N, Lindner S**  
Internet-based relapse prevention for anorexia nervosa: nine-month follow-up.  
J Eating Disorders 2013; 1: 23. IF -
54. **Gaebel W, Zielasek J, Falkai P**  
Psychische Gesundheit und die Arbeitswelt – Mental health and the workplace.  
Die Psychiatrie 2013; 10: 59-60. IF -
55. **Gebicke-Haerter PJ, Pildain LV, Matthäus F, Schmitt A, Falkai P**  
Circadian rhythms investigated on the cellular and molecular levels.  
Pharmacopsychiatry 2013; 46 Suppl 1: S22-S29. IF 2.168
56. **Genius J, Geiger J, Dölzer AL, Benninghoff J, Giegling I, Hartmann AM, Möller H-J, Rujescu D**  
Glutamatergic dysbalance and oxidative stress in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism.  
PLoS One 2013; 8: e59395. IF 3.534
57. **Giegling I, Balzarro B, Porcelli S, Schäfer M, Hartmann AM, Friedl M, Konte B, Krämer P, Möller H-J, de Ronchi D, Stassen HH, Serretti A, Rujescu D**



Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 65-74. IF 3.355

58. **Girma E, Tesfaye M, Froeschl G, Möller-Leimkühler AM, Dehning S, Müller N**  
Facility based cross-sectional study of self stigma among people with mental illness: towards patient empowerment approach.  
Int J Ment Health Syst 2013; 7: 21. IF -
  
59. **Girma E, Tesfaye M, Froeschl G, Möller-Leimkühler AM, Müller N, Dehning S**  
Public stigma against people with mental illness in the Gilgel Gibe Field Research Center (GGFRC) in Southwest Ethiopia.  
PLoS One 2013; 8: e82116. IF 3.534
  
60. **Godemann F, Falkai P, Hauth I, Salize H-J, Pollmächer T, Wolff-Menzler C**  
Pauschalierendes Entgeltsystem in der Psychiatrie und Psychosomatik.  
Begleitforschung – quo vadis?  
Nervenarzt 2013; 84: 864-868. IF 0.862
  
61. **Greil W, Häberle A, Schuhmann T, Grohmann R, Baumann P**  
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.  
Swiss Med Weekly 2013; 143: w13772. IF 1.877
  
62. **Greil W, Poppe**  
Psychologen in der Psychiatrie: Beispiel Psychiatrische Privatklinik Sanatorium Kilchberg bei Zürich.  
In: Znoj HJ, Berger T (Hrsg). Die Kunst und Wissenschaft der Psychotherapie. Huber, Bern, 2013, S. 251-254.
  
63. **Großheinrich N, Reinl M, Pogarell O, Karch S, Mulert C, Brueckl M, Hennig-Fast K, Rau A, Epple M, Hornig A, Padberg F**  
Effects of low frequency prefrontal transcranial magnetic stimulation on the N2 amplitude in a GoNogo Task.  
PLoS One 2013; 8: e67136. IF 3.534
  
64. **Großimlinghaus I, Falkai P, Gaebel W, Janssen B, Reich-Erkelenz D, Wobrock T, Zielasek J**  
Entwicklungsprozess der DGPPN-Qualitätsindikatoren.  
Nervenarzt 2013; 84: 350-365. IF 0.862
  
65. **Grunze A, Meisenzahl E, Grunze H**  
Bildgebende Verfahren bei bipolaren Erkrankungen.  
Fortschr Neurol Psychiatr 2013; 81 Suppl 1: S17-21. IF 0.762

66. **Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller H-J, Kasper S on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders.**  
The World Federation of societies of biological psychiatry (WFSBP). Guidelines for the biological treatment of bipolar disorders: update 2013 on the long-term treatment of bipolar disorder.  
World J Biol Psychiatry 2013; 14: 154-219. IF 4.225
67. **Gu S, Fellerhoff B, Müller N, Laumbacher B, Wank R**  
Paradoxical downregulation of HLA expression by IFN $\gamma$  associated with schizophrenia and noncoding genes.  
Immunobiology 2013; 218: 738-744. IF 3.180
68. **Guest PC, Martins-de-Souza, Schwarz E, Rahmoune H, Alsaif M, Tomasik J, Turck CW, Bahn S**  
Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.  
Genome Med 2013; 5: 25. IF 4.942
69. **Haas I, Grohmann R, Rüter E, Degner D**  
Durch Trimipramin induzierte Zwangsstörung.  
Psychopharmakotherapie 2013; 20: 82-87. IF -
70. **Hasan A, Bergener T, Nitsche MA, Strube W, Bunse T, Falkai P, Wobrock T**  
Impairment of motor-cortex responses to unilateral and bilateral direct current stimulation in schizophrenia.  
Front Psychiatry 2013; 4: 121. IF -
71. **Hasan A, Falkai P, Wobrock T**  
Transcranial brain stimulation in schizophrenia: targeting cortical excitability, connectivity and plasticity.  
Curr Med Chem 2013; 20: 405-413. IF 3.715
72. **Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller H-J, WFSBP Task Force on Treatment Guidelines for Schizophrenia**  
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia, part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.  
World J Biol Psychiatry 2013; 14: 2-44. IF 4.225
73. **Hasan A, Galea JM, Casula EP, Falkai P, Bestmann S, Rothwell JC**  
Muscle and timing-specific functional connectivity between the dorsolateral prefrontal cortex and the primary motor cortex.  
J Cogn Neurosci 2013; 25: 558-570. IF 4.687

74. **Hasan A, Misewitsch K, Nitsche MA, Gruber O, Padberg F, Falkai P, Wobrock T**  
Impaired motor cortex responses in non-psychotic first-degree relatives of schizophrenia patients: a cathodal tDCS pilot study.  
*Brain Stimul* 2013; 6: 821-9. IF 5.432
75. **Hasan A, Mitchell A, Schneider A, Akbarian S**  
Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors.  
*Eur Arch Psychiatry Clin Neurosci* 2013; 263: 273-84. IF 3.355
76. **Hasan A, Schneider M, Schneider-Axmann T, Ruge D, Retz W, Rösler M, Falkai P, Wobrock T**  
A similar but distinctive pattern of impaired cortical excitability in first-episode schizophrenia and ADHD.  
*Neuropsychobiology* 2013; 67: 74-83. IF 2.303
77. **Hasan A, Wobrock T**  
Biologische Behandlung der therapieresistenten Schizophrenie.  
*Fortschr Neurol Psychiatr* 2013; 81: 464-472. IF 0.762
78. **Hasan A, Wobrock T, Gaebel W, Janssen B, Zielasek J, Falkai P**  
Nationale und internationale Leitlinien zur Schizophrenie. Update 2013 zum Stand der Empfehlungen zur antipsychotischen Medikation.  
*Nervenarzt* 2013; 84: 1359-1368. IF 0.862
79. **Hasan A, Wobrock T, Rajji T, Malchow B, Daskalakis ZJ**  
Modulating neural plasticity with non-invasive brain stimulation in schizophrenia.  
*Eur Arch Psychiatry Clin Neurosci* 2013; 263: 621-31. IF 3.355
80. **Hashimoto K, Malchow B, Falkai P, Schmitt A**  
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.  
*Eur Arch Psychiatry Clin Neurosci* 2013; 263: 367-77. IF 3.355
81. **Hennings A, Schwarz MJ, Riemer S, Stapf TM, Selberdinger VB, Rief W**  
Exercise affects symptom severity but not biological measures in depression and somatization – results on IL-6, neopterin, tryptophan, kynurenine and 5-HIAA.  
*Psychiatry Res* 2013; 210: 925-933. IF 2.682
82. **Iwata K, Café-Mendes CC, Schmitt A, Steiner J, Manabe T, Matsuzaki H, Falkai P, Turck CW, Martins-de-Souza D**  
The human oligodendrocyte proteome.  
*Proteomics* 2013; 13: 3548-53. IF 3.973

83. **Jatzko A, Vogler C, Demirakca T, Ruf M, Malchow B, Falkai P, Braus DF, Ende G, Schmitt A**  
Pattern and volume of the anterior cingulate cortex in chronic posttraumatic stress disorder (PTSD)  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 585-592. IF 3.355
84. **Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Orahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K**  
Variant of TREM2 associated with the risk of Alzheimer's disease.  
N Engl J Med 2013; 368: 107-116. IF 54.420
85. **Kanwar J, Okusaga O, Giegling I, Konte B, Vaswani D, Sleemi A, Vaswani R, Hartmann AM, Friedl M, Hong LE, Reeves G, Stephens S, Dixon L, Rujescu D, Postolache TT**  
In patients with schizophrenia, non-fatal suicidal self-directed violence is positively associated with present but not past smoking.  
Schizophr Res 2013; 149: 194-195. IF 4.426
86. **Karagiannidis I, Dehning S, Sandor P, Tarnok Z, Rizzo R, Wolanczyk T, Madruga-Garrido M, Hebebrand J, Nöthen MM, Lehmkuhl G, Farkas L, Nagy P, Szymanska U, Anastasiou Z, Stathias V, Androutsos C, Tsironi V, Koumoula A, Barta C, Zill P, Mir P, Müller N, Barr C Paschou P**  
Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families.  
J Med Genet 2013; 50: 760-764. IF 5.636
87. **Koch S, Quadflieg N, Fichter M**  
Purging disorder: a comparison to established eating disorders with purging behaviour.  
Eur Eat Disord Rev 2013; 21: 265-275. IF -
88. **Koch S, Quadflieg N, Rief W, Fichter M**  
Purging-Störung – eine eigenständige Diagnose? Ein Überblick zum aktuellen Stand der Forschung.  
Psychother Psychosom Med Psychol 2013; 63: 305-17. IF -
89. **Köster M, Grohmann R, Engel RR, Nitsche MA, Rüter E, Degner D**  
Seizures during antidepressant treatment in psychiatric inpatients – results from the transnational pharmacovigilance project “Arzneimittelsicherheit in der Psychiatrie” (AMSP) 1993-2008.  
Psychopharmacology 2013; 230: 191-201. IF 3.988

90. **Koller G**  
Langzeittherapie der Alkoholabhängigkeit.  
Fortschr Neurol Psychiatr 2013; 81: 655-666. IF 0.762
91. **Koutsouleris N, Ruhrmann S**  
Personalisierte Medizin in der Psychiatrie und Psychotherapie.  
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56:  
1522-30. IF -
92. **Krause DL, Matz J, Schennach R, Müller N, Dehning S**  
Ziprasidone for obsessive compulsive disorder in schizophrenia.  
Ther Adv Psychopharmacol 2013; 3: 115-116. IF -
93. **Krause D, Weidinger E, Dippel C, Riedel M, Schwarz MJ, Müller N, Myint A-M**  
Impact of different antipsychotics on cytokines and tryptophan metabolites  
stimulated cultures from patients with schizophrenia.  
Psychiat Danub 2013; 25: 389-397. IF 0.653
94. **Lange-Asschenfeldt C, Kojda G, Cordes J, Hellen F, Gillmann A,  
Grohmann R, Supprian T**  
Epidemiology, symptoms, and treatment characteristics of Hyponatremic  
psychiatric inpatients.  
J Clin Psychopharmacol 2013; 33: 799-805. IF 3.761
95. **Leicht G, Mulert C, Eser D, Sämann PG, Ertl M, Laenger A, Karch S,  
Pogarell O, Meindl T, Czisch M, Rupprecht R**  
Benzodiazepine counteract rostral anterior cingulate cortex activation induced  
by cholecystokinin-tetrapeptide in humans.  
Biol Psychiatry 2013; 73: 337-44. IF 9.472
96. **Lennertz L, Franke PE, Grabe HJ, Rampacher F, Schulze-Rauschenbach S,  
Guttenthaler V, Ruhrmann S, Pukrop R, Klosterkötter J, Falkai P, Maier  
W, Wagner M, Mössner R**  
The functional coding variant Asn107Ile of the neuropeptide S receptor gene  
(NPSR1) influences age at onset of obsessive-compulsive disorder.  
Int J Neuropsychopharmacol 2013; 16: 1951-1958. IF 5.264
97. **Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M,  
Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti  
G, Davis JM**  
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia:  
a multiple-treatments meta-analysis.  
Lancet 2013; 382: 951-962. IF 39.207

98. **Leucht S, Fennema H, Engel R, Kaspers-Jannsen M, Lepping P, Szegedi A**  
What does the HAMD mean?  
*J Affect Disord* 2013; 148: 243-248. IF 3.705
99. **Leucht S, Rothe P, Davis JM, Engel RR**  
Equipercetile linking of the BPRS and the PANSS.  
*Eur Neuropsychopharmacol* 2013; 23: 956-959. IF 5.395
100. **Lieb M, Palm U, Chiang S, Laubender RP, Nothdurfter C, Sarubin N, Mokhtari-Nejad R, Koller G, Soyka M**  
Pharmacological challenge with naloxone and cue exposure in alcohol dependence: results of a randomized, double-blind placebo-controlled trial.  
*World J Biol Psychiatry* 2013; 14: 539-546. IF 4.225
101. **Lindner SE, Fichter MM, Quadflieg N**  
Central coherence in full recovery of anorexia nervosa.  
*Eur Eat Disord Rev* 2013; 21: 115-120. IF -
102. **Maccarone G, Rewerts C, Lebar M, Turck CW, Martins-de-Souza D**  
Proteome profiling of peripheral mononuclear cells from human blood.  
*Proteomics* 2013; 13: 893-897. IF 3.973
103. **Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T**  
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence.  
*Eur Arch Psychiatry Clin Neurosci* 2013; 263: 3-13. IF 3.355
104. **Malchow B, Hasan A, Schneider-Axmann T, Jatzko A, Gruber O, Schmitt A, Falkai P, Wobrock T**  
Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia.  
*Eur Arch Psychiatry Clin Neurosci* 2013; 263 Suppl2: S155-S168. IF 3.355
105. **Malchow B, Reich-Erkelenz D, Oertel-Knöchel V, Keller K, Hasan A, Schmitt A, Scheewe TW, Cahn W, Kahn RS, Falkai P**  
The effects of physical exercise in schizophrenia and affective disorders.  
*Eur Arch Psychiatry Clin Neurosci* 2013; 263: 451-467. IF 3.355
106. **Manchia M, Adli M, Akula N, Ardaur R, Aubry J-M, Backlund L, Banzato CEM, Baune BT, Bellilvier F, Bengesser S, Biernacka JM, Brichtant-Petitjean C, Bui E, Calkin CV, Cheng ATA, Chillotti C, Cichon S, Clark S, Czerski PM, Dantas C, del Zompo M, dePaulo JR, Detera-Wadleigh SD, Etain B, Falkai P, Frisé L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hou L, Jamain S, Kahn J-P, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwicky S, Kuo P-H, Kusumi I, Laje G, Lavebratt C, Leboyer**

**M, Leckband SG, Jaramillo CAL, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell PB, Mondimore F, Monteleone P, Nallet A, Neuner M, Novák T, O'Donnovan C, Ösby U, Ozaki N, Perlis RH, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert OK, Schweizer B, Seemüller F, Grigoriu-Serbanescu M, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe SK, Tortorella A, Turecki G, Wray NR, Wright A, Zandi PP, Zilles D, Bauer M, Rietschel M, McMahon FJ, Schulze TG, Alda M**  
Assessment of response to lithium maintenance treatment in bipolar disorder: a consortium on lithium genetics (ConLiGen) report.  
PLOS One 2013; 8: e65636. IF 3.534

107. **Martins-de-Souza D**  
Biomarkers for psychiatric disorders: where are we standing?  
Dis Markers 2013; 35: 1-2. IF 2.174
108. **Möller-Leimkühler AM**  
Die psychotherapeutische Versorgung psychisch kranker Männer – Impulse aus der Forschung.  
Psychotherapie aktuell 2013; 2: 4-6. IF -
109. **Möller-Leimkühler AM**  
Komorbidität psychischer und somatischer Erkrankungen bei Männern. Ein Problemaufriss.  
In: Weißbach L, Stiehler M (Hrsg). Männergesundheitsbericht 2013. Im Fokus: Psychische Gesundheit.  
Hans Huber, Bern, 2013; S. 83-102.
110. **Möller-Leimkühler AM**  
Psychische Gesundheit von Männern: Bedeutung, Ziele, Handlungsbedarf.  
In: Weißbach L, Stiehler M (Hrsg). Männergesundheitsbericht 2013. Im Fokus: Psychische Gesundheit.  
Hans Huber, Bern, 2013, S. 63-82.
111. **Möller-Leimkühler AM, Bogerts B**  
Kollektive Gewalt. Neurobiologische, psychosoziale und gesellschaftliche Bedingungen.  
Nervenarzt 2013; 84: 1344-58. IF 0.862
112. **Montag C, Brockmann E-M, Bayerl M, Rujescu D, Müller DJ, Gallinat J**  
Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study:  
World J Biol Psychiatry 2013; 14: 500-508. IF 4.225
113. **Müller JL, Falkai P, Schneider P, Hauth I, Maier W**  
Psychiatrie im Spannungsfeld zwischen Gefahrenabwehr und Therapie:

Zwangsbehandlung in der Zeit nach der Rechtsprechung des Bundesverfassungsgerichts und des Bundesgerichtshofs.  
Psychiatr Prax 2013; 40: 365-367. IF -

114. **Müller N**  
The role of anti-inflammatory treatment in psychiatric disorders.  
Psychiatr Danub 2013; 25: 292-298. IF 0.653
115. **Müller N, Bechter K**  
The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings.  
Neurology Psychiatry Brain Research 2013; 19: 87-101. IF -
116. **Müller N, Myint A-M, Krause D, Weidinger E, Schwarz MJ**  
Anti-inflammatory treatment in schizophrenia.  
Prog Neuro-Psychopharmacol Biol Psychiatry 2013; 42: 146-153.  
IF 4.025
117. **Müller S, Keeser D, Samson AC, Kirsch V, Blautzik J, Grothe M, Erat O, Hegenloh M, Coates U, Reiser MF, Hennig-Fast K, Meindl T**  
Convergent findings of altered functional and structural brain connectivity in individuals with high functioning autism: a multimodal MRI study.  
PLoS One 2013; 8: e67329. IF 3.534
118. **Musil R, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, Adli M, Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller H-J, Riedel M**  
Genetics of emergent suicidality during antidepressive treatment – data from a naturalistic study on a large sample of inpatients with a major depressive episode.  
Eur Neuropsychopharmacol 2013; 23: 663-674. IF 5.395
119. **Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller H-J, Riedel M**  
No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 405-12. IF 3.355
120. **Myint AM, Bondy B, Baghai TC, Eser D, Nothdurfter C, Schüle C, Zill P, Müller N, Rupprecht R, Schwarz MJ**  
Tryptophan metabolism and immunogenetics in major depression: a role for interferon- $\gamma$  gene.  
Brain Behav Immun 2013; 31: 128-133. IF 6.128



121. **Naab S, Schlegl S, Korte A, Heuser J, Fumi M, Fichter M, Cuntz U, Voderholzer U**  
Effectiveness of a multimodal inpatient treatment for adolescents with anorexia nervosa in comparison with adults: an analysis of a specialized inpatient setting: treatment of adolescent and adult anorexics.  
*Eat Weight Disord* 2013; 18: 167-73. IF 0.680
122. **Nedopil N, Boetticher A**  
Begutachtungen zur Schuldunfähigkeit und verminderten Schuldfähigkeit.  
*Die Psychiatrie* 2013; 10: 152-159. IF -
123. **Nedopil N, Müller JL**  
Forensische Psychiatrie und Psychotherapie.  
*Die Psychiatrie* 2013; 10: 139-140. IF -
124. **Nischalke HD, Berger C, Lutz P, Langhans B, Wolter F, Eisenhardt M, Krämer B, Kokordelis P, Glässner A, Müller T, Rosendahl J, Fischer J, Berg T, Grünhage F, Leifeld L, Soyka M, Nattermann J, Sauerbruch T, Stickel F, Spengler U**  
Influence of the CXCL1 rs4074 allele on alcohol induced cirrhosis and HCC in patients of European descent.  
*PLoS One* 2013; 8: e80848. IF 3.534
125. **Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU**  
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.  
*Schizophr Bull* 2013; 39: 1230-1241. IF 8.607
126. **Nowidi K, Kunisch R, Bouna-Pyrrou P, Meißner D, Hennig-Fast K, Weindl A, Förster S, Neuhamm TM, Falkai P, Berger M, Musil R**  
White man's burden – im Grenzgebiet zwischen bipolarer affektiver Störung and Huntington-Erkrankung.  
*Fortschr Neurol Psychiatr* 2013; 81: 337-45. IF 0.762
127. **Östling S, Bäckman K, Waern M, Marlow T, Braam AW, Fichter M, Lawlor BA, Lobos A, Reischies FM, Copeland JRM, Skoog I**  
Paranoid symptoms and hallucinations among the older people in Western Europe.  
*Int J Geriatr Psychiatry* 2013; 28: 573-579. IF 3.086
128. **Okusaga O, Yolken RH, Langenberg P, Sleemi A, Kelly DL, Vaswani D, Giegling I, Hartmann AM, Konte B, Friedl M, Mohyuddin F, Groer MW, Rujescu D, Postolache TT**  
Elevated gliadin antibody levels in individuals with schizophrenia.  
*World J Biol Psychiatry* 2013; 14: 509-515. IF 4.225

129. **Oliveira BM, Schmitt A, Falkai P, Martins-de-Souza D**  
Is clinical proteomics heading towards to “bench to bedside”?  
Translational Proteomics 2013; 1: 53-56. IF -
130. **Palm U, Fintescu Z, Obermeier M, Schiller C, Reisinger E, Keeser D, Pogarell O, Bondy B, Zill P, Padberg F**  
Serum levels of brain-derived neurotrophic factor are unchanged after transcranial direct current stimulation in treatment-resistant depression.  
J Affect Disord 2013; 150: 659-63. IF 3.705
131. **Palm U, Hasan A, Keeser D, Bunse T, Padberg F**  
Neue Hirnstimulationsverfahren in der Psychiatrie.  
Nervenheilkunde 2013; 32: 866-876. IF -
132. **Palm U, Hasan A, Keeser D, Falkai P, Padberg F**  
Transcranial random noise stimulation for the treatment of negative symptoms in schizophrenia.  
Schizophr Res 2013; 146: 372-3. IF 4.426
133. **Palm U, Keeser D, Blautzik J, Pogarell O, Ertl-Wagner B, Kupka MJ, Reiser M, Padberg F**  
Prefrontal transcranial direct current stimulation (tDCS) changes negative symptoms and functional connectivity MRI (fcMRI) in a single case of treatment-resistant schizophrenia.  
Schizophr Res 2013; 150: 583-5. IF 4.426
134. **Palm U, Reisinger E, Keeser D, Kuo MF, Pogarell O, Leicht G, Mulert C, Nitsche MA, Padberg F**  
Evaluation of sham transcranial direct stimulation for randomized, placebo-controlled clinical trials.  
Brain Stimul 2013; 6: 690-5. IF 5.432
135. **Peselmann N, Schmitt A, Gebicke-Haerter PJ, Zink M**  
Aripiprazole differentially regulates the expression of Gad67 and  $\gamma$ -aminobutyric acid transporters in rat brain.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 285-297. IF 3.355
136. **Pfennig A, Bschor T, Falkai P, Bauer M**  
Diagnostik und Therapie bipolarer Störungen.  
Dtsch Arztebl PP 2013; 129-137. IF -
137. **Pfennig A, Bschor T, Falkai P, Bauer M**  
The diagnosis and treatment of bipolar disorder: recommendations from the current S3 Guideline.  
Dtsch Arztebl Int 2013; 110: 92-100. IF -

138. **Pilurzi G, Hasan A, Saifee TA, Tolu E, Rothwell JC, Deriu F**  
Intracortical circuits, sensorimotor integration and plasticity in human motor cortical projections to muscles of the lower face.  
J Physiol 2013; 591: 1889-1906. IF 4.544
139. **Plate A, Benninghoff J, Jansen GH, Wlasich E, Eigenbrod S, Drzezga A, Jansen NL, Kretzschmar HA, Bötzel K, Rujescu D, Danek A**  
Atypical parkinsonism due to a D202N Gerstmann-Sträussler-Scheinker prion protein mutation: first in vivo diagnosed case.  
Mov Disord 2013; 28: 241-244. IF 5.634
140. **Preuss UW, Winham SJ, Biernacka JM, Geske JR, Bakalkin G, Koller G, Zill P, Soyka M, Karpyak VM**  
PDYN rs2281285 variant association with drinking to avoid emotional of somatic discomfort.  
PLoS One 2013; 8: e78688. IF 3.534
141. **Preuss UW, Wurst FM, Ridinger M, Rujescu D, Fehr C, Koller G, Bondy B, Wodarz N, Soyka M, Zill P**  
Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: results from a large multicentre association study.  
Drug Alcohol Depend 2013; 133: 459-467. IF 3.278
142. **Priebe L, Degenhardt F, Strohmaier J, Breuer R, Herms S, Witt SH, Hoffmann P, Kulbida R, Mattheisen M, Moebus S, Meyer-Lindenberg A, Walter H, Mössner R, Nenadic I, Sauer H, Rujescu D, Maier W, Rietschel M, Nöthen MM, Cichon S**  
Copy number variants in German patients with schizophrenia.  
PLoS One 2013; 8: e64035. IF 3.534
143. **Rice SM, Fallon BJ, Aucote H, Möller-Leimkühler AM**  
Development and preliminary validation of the male depression risk scale: Furthering the assessment of depression in men.  
J Affect Disord 2013; 151: 950-958. IF 3.705
144. **Riegg F, Pogarell O**  
Alkoholmissbrauch und Alkoholabhängigkeit bei Kindern und Jugendlichen in Deutschland.  
tägl prax 2013; 54: 115-123. IF -
145. **Rösner S, Soyka M, Hajak G, Wehrle R, Englbrecht C**  
Eszopiclone for insomnia.  
Cochrane Database Syst Rev (CDSR), August 2013 (Protocol). IF 5.939

146. **Rösner S, Soyka M, Hajak G, Wehrle R, Englbrecht C**  
Zaleplon for insomnia.  
Cochrane Database Syst Rev (CDSR), August 2013 (Protocol). IF 5.939
  
147. **Rösner S, Soyka M, Hajak G, Wehrle R, Englbrecht C**  
Zolpidem for insomnia.  
Cochrane Database Syst Rev (CDSR), August 2013 (Protocol). IF 5.939
  
148. **Rösner S, Soyka M, Hajak G, Wehrle R, Englbrecht C**  
Zopiclone for insomnia.  
Cochrane Database Syst Rev (CDSR), August 2013 (Protocol). IF 5.939
  
149. **Rominger A, Cumming P, Xiong G, Koller G, Förster S, Zwergal A, Karamatskos E, Bartenstein P, la Fougère C, Pogarell O**  
Effects of acute detoxification of the herbal blend 'Spice Sold' on dopamine D<sub>2</sub>/D<sub>3</sub> receptor availability: a [<sup>18</sup>F]fallypride PET study.  
Eur Neuropsychopharmacol 2013; 23: 1606-10. IF 5.395
  
150. **Samara MT, Spineli LM, Furukawa TA, Engel RR, Davis JM, Salanti G, Leucht S**  
Imputation of response rates from means and standard deviations in schizophrenia.  
Schiz Res 2013; 151: 209-214. IF 4.426
  
151. **Schaeffer EL, Kühn F, Schmitt A, Gattaz WF, Gruber O, Schneider-Axmann T, Falkai P, Schmitt A**  
Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia.  
J Neural Transm 2013; 120: 187-195. IF 2.871
  
152. **Schaub A**  
Bipolare Störungen – Psychoedukation im Kontext neurobiologischer Erkenntnisse und optimierter Therapie.  
Fortschr Neurol Psychiatr 2013; 81 Suppl 1: S1-S2. IF 0.762
  
153. **Schaub A, Neubauer N**  
Psychotherapie bei bipolaren Störungen – Therapiekonzepte, ihre Inhalte und Wirksamkeit.  
Fortschr Neurol Psychiatr 2013; 81 Suppl 1: S22-S29. IF 0.762
  
154. **Schaub A, Neubauer N, Bernhard B, Born C, Möller H-J, Grunze H**  
Kognitiv-psychoedukative Gruppenintervention bei bipolar erkrankten Patienten: Pilotstudie mit Zwei-Jahres-Katamnese.  
Fortschr Neurol Psychiatr 2013; 81 Suppl 1: S30-S34. IF 0.762

155. **Schaub A, Neubauer N, Mueser KT, Engel R, Möller H-J**  
Neuropsychological functioning in inpatients with major depression of schizophrenia.  
BMC Psychiatry 2013; 13: 203. IF 2.237
156. **Schaub A, Roth E, Goldmann U**  
Kognitiv-psychoedukative Therapie zur Bewältigung von Depressionen.  
Ein Therapiemanual. Hogrefe, Göttingen, 2013.
157. **Schennach R, Riesbeck M, Mayr A, Seemüller F, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Sauer H, Schneider F, Jäger M, Wölwer W, Gaebel W, Möller H-J, Riedel M**  
Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?  
Acta Psychiatr Scand 2013; 127: 474-481. IF 5.545
158. **Schicho W, Pogarell O**  
Wichtige Ergänzung zur Rezidivprophylaxe und Trinkmengenreduktion.  
DNP Der Neurologe & Psychiater 2013; 14: 2-6. IF -
159. **Schiepek G, Tominschek I, Heinzl S, Aigner M, Dold M, Unger A, Lenz G, Windischberger C, Moser E, Plöderl M, Lutz J, Meindl T, Zaudig M, Pogarell O, Karch S**  
Discontinuous patterns of brain activation in the psychotherapy process of obsessive-compulsive disorder: converging results from repeated fMRI and daily self-reports.  
PLoS One 2013; 8: e71863. IF 3.534
160. **Schmitt A**  
Weniger Symptome, bessere Fitness.  
InFo Neurologie 2013; 15: 10. IF -
161. **Schmitt A, Falkai P**  
Brain imaging to be on track for improving diagnosis and pathophysiological insights in neuropsychiatric diseases.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 537-538. IF 3.355
162. **Schmitt A, Falkai P**  
Differential diagnosis of major depression and bipolar disorder.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 83-4. IF 3.355
163. **Schmitt A, Falkai P**  
Impact of lifestyle in severe psychiatric disorders and brain morphology.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 449-450. IF 3.355

164. **Schmitt A, Falkai P**  
Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 271-272. IF 3.355
165. **Schmitt A, Falkai P**  
Risk genes, metabolic syndrome and eye tracking deficits in psychiatric diseases.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 177-179. IF 3.355
166. **Schmitt A, Falkai P**  
Schizophrenia: brain morphology and treatment aspects.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 1-2. IF 3.355
167. **Schmitt A, Falkai P**  
Selected topics of the DGPPN Congress 2012.  
Eur Arch Psychiatry Clin Neurosci 2013; 263 Suppl 2: S121-S122.  
IF 3.355
168. **Schmitt A, Falkai P**  
The glutamate system as a therapeutic target and impact of genes on suicidality.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 365-366. IF 3.355
169. **Schmitt A, Falkai P**  
Therapeutic targets in major psychiatric disorders revisited.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 619-20. IF 3.355
170. **Schmitt A, Reich-Erkelenz D, Gebicke-Härter P, Falkai P**  
Transcriptome studies in the context of disturbed connectivity in schizophrenia.  
Rev Psiq Clin 2013; 40: 10-15. IF -
171. **Schmitt A, Turck CW, Pilz PK, Malchow B, von Wilmsdorff M, Falkai P, Martins-de-Souza D**  
Protomic similarities between heterozygous reeler mice and schizophrenia.  
Biol Psychiatry 2013; 74: e5-e10. IF 9.472
172. **Schwarz MJ, Guillemin GJ, Teipel SJ, Buerger K, Hampel H**  
Increased 3-hydroxykynurenine serum concentrations differentiale Alzheimer's disease patients from controls.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 345-352. IF 3.355
173. **Seemüller F, Berger M, Musil R, Severus E, Dittmann S, Born C, Schaub A, Dargel S, Grunze H**  
Herausforderungen der ambulanten Behandlung von Patienten mit bipolar-affektiven Störungen.  
Fortschr Neurol Psychiatr 2013; 81 Suppl 1: S35-S39. IF 0.762

174. **Segmiller F, Frisse D, Eser D, Möller H-J, Schüle C**  
Ketamin zur Behandlung der therapieresistenten Depression. Ein Fallbericht.  
Nervenarzt 2013; 84: 854-855. IF 0.862
175. **Segmiller FM, Hermisson I, Riedel M, Seemüller F, Volkamer T, Laux G, Möller H-J, Brunnauer A**  
Driving ability according to german guidelines in stabilized bipolar I and II outpatients receiving lithium or lamotrigine.  
J Clin Pharmacol 2013; 53: 459-462. IF 2.472
176. **Segmiller FM, Rütther M, Linhardt A, Dehning S, Möller H-J, Zetzsche T**  
Psychosis during treatment with isotretinoin.  
Ther Adv Psychopharmacol 2013; 3: 244-245. IF -
177. **Segmiller F, Rütther T, Linhardt A, Padberg F, Berger M, Pogarell O, Möller H-J, Kohler C, Schüle C**  
Repeated S-ketamine infusions in therapy resistant depression: a case series.  
J Clin Pharmacol 2013; 53: 996-998. IF 2.472
178. **Severus E, Lipkovich I, Seemüller F, Obermeier M, Grunze H, Bernhard B, Dittman S, Riedel M, Möller H-J**  
The potential role of marginal structural models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice.  
World J Biol Psychiatry 2013; 14: 386-395. IF 4.225
179. **Soutschek A, Schwarzkopf W, Finke K, Hennig-Fast K, Müller H-J, Riedel M, Möller H-J, Sorg C, Schubert T**  
Interference control in adult ADHD: no evidence for interference control deficits if response speed is controlled by delta plots.  
Acta Psychol 2013; 143: 71-78. IF -
180. **Soyka M**  
Affektive und Angststörungen und Substanzabhängigkeit.  
Suchtmed 2013; 15: 341-348. IF -
181. **Soyka M**  
Affektive Störungen und Sucht.  
neuro aktuell 2013; 7: 20-21. IF -
182. **Soyka M**  
Buprenorphine and buprenorphine/naloxone intoxication in children – how strong is the risk?  
Curr Drug Abus Rev 2013; 6: 63-70. IF -

183. **Soyka M**  
Buprenorphine use in pregnant opioid users: a critical review.  
CNS Drugs 2013; 27: 653-662. IF 4.376
184. **Soyka M**  
Drug therapy: reviewing the evidence.  
In: Boyle P, Boffetta P, Lowenfels AB, Burns H, Brawley O, Zatonski W, Rehm J  
Oxford University Press, 2013, S. 332-339.
185. **Soyka M**  
Epidemiologie und Behandlung der Alkoholabhängigkeit.  
NeuroTransmitter 2013; 24: 40-43. IF -
186. **Soyka M**  
Evidenzbasierte Richtlinien zur Behandlung.  
Info Neurologie Psychiatrie 2013; 11: 7-11. IF -
187. **Soyka M**  
Evidenzbasierte Therapie.  
neuropsy 2013: 16-23. IF -
188. **Soyka M**  
Treatment of anxiety in substance-using patients.  
Interventions for addiction 2013; 3: 489-495. IF -
189. **Soyka M, Batra A**  
Benzodiazepinabhängigkeit (ICD-10 F.13.2)  
In: Voderholzer U, Hohagen F (Hrsg.)  
Therapie psychischer Erkrankungen. State of the art 2012/2013.  
Urban & Fischer, München, 2013, S.53-60.
190. **Soyka M, Helten B, Cleves M, Schmidt P**  
High rehospitalisation rate in alcohol-induced psychotic disorder.  
Eur Arch Psychiatry Clin Neurosci 2013; 263: 309-313. IF 3.355
191. **Soyka M, Peters L, Schmidt P, Haberthür A**  
Comparison of cognitive functioning in abstinent opiate-dependent individuals,  
methadone-maintenance patients and healthy controls: study protocol and  
update of the existing literature.  
Neuropsychiatry 2013; 3: 611-620. IF 0.615
192. **Soyka M, Stickel F**  
Psychiatrische Begutachtung zur Transplantationsfähigkeit bei Patienten mit  
alkoholischer Leberzirrhose.  
Nervenarzt 2013; 84: 1075-1080. IF 0.862



193. **Stadtland C, Kainz WJ, Nedopil N**  
Vermeidbare Fehler bei sozialmedizinischen Gutachten.  
Die Psychiatrie 2013; 10: 195-201. IF -
194. **Stübner S, Grohmann R, Schmauß M**  
Arzneimittelsicherheit in der klinischen Praxis – Teil 2:  
Klinisch relevante Aspekte aus Medizinhistorie, Wissenschaft, Ökonomie und  
Forensik.  
Fortschr Neurol Psychiatr 2013; 81: 715-729. IF 0.762
195. **Taverna M, Straub T, Hampel H, Rujescu D, Lichtenthaler SF**  
A new sandwich immunoassay for detection of the  $\alpha$ -secretase cleaved, soluble  
amyloid- $\beta$  protein precursor in cerebrospinal fluid and serum.  
J Alzheim Dis 2013; 37: 667-678. IF 3.612
196. **Taylor PJ, Woolfenden N, Nedopil N**  
Forensic psychiatry training in Europe.  
Die Psychiatrie 2013; 10: 181-187. IF -
197. **Tesfay K, Girma E, Negash A, Tesfaye M, Dehning S**  
Medication non-adherence among adult psychiatric out patients in Jimma  
University Specialized Hospital, Southwest Ethiopia.  
Ethiop J Health Sci 2013; 23: 227-236. IF -
198. **Tretter F, Pogarell O, Rujescu D, Meisenzahl E, Mewes HW**  
Systems biology of oscillatory processes in sleep and mental disorders.  
Pharmacopsychiatry 2013; 46 Suppl 1: S1. IF 2.168
199. **Trost S, Platz B, Usher J, Scherk H, Wobrock T, Ekawardhani S, Meyer J,  
Reith W, Falkai P, Gruber O**  
DISC1 (disrupted-in-schizophrenia 1) is associated with cortical grey matter  
volumes in the human brain: a voxel-based morphometry (VBM) study.  
J Psychiatr Res 2013; 47: 188-96. IF 4.092
200. **Von Wilmsdorff M, Blaich C, Zink M, Treutlein J, Bauer M, Schulze T,  
Schneider-Axmann T, Gruber O, Rietschel M, Schmitt A, Falkai P**  
Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in  
the cerebellar subregions of elderly schizophrenia patients and effects of  
antipsychotic treatment.  
World J Biol Psychiatry 2013; 14: 490-499. IF 4.225
201. **Von Wilmsdorff M, Bouvier M-L, Henning U, Schmitt A, Schneider-  
Axmann T, Gaebel W**  
The sex-dependent impact of chronic clozapine and haloperidol treatment on  
characteristics of the metabolic syndrome in a rat model.  
Pharmacopsychiatry 2013; 46: 1-9. IF 2.168

202. **Vossler-Thies E, Stevens A, Engel RR, Licha C**  
Erfassung negative Antwortverzerrungen mit der deutschen Fassung des  
"Personality Assessment Inventory", dem "Verhaltens- und Erlebnisinventar".  
Diagnostica 2013; 59: 73-85. IF -
203. **Walters JT, Rujescu D, Franke B, Giegling I, Vásquez AA, Hargreaves A,  
Russo G, Morris DW, Hoogman M, Da Costa A, Moskvina V, Fernández  
G, Gill M, Corvin A, O'Donovan MC, Donohoe G, Owen MJ**  
The role of the major histocompatibility complex region in cognition and brain  
structure: a schizophrenia GWAS follow-up.  
Am J Psychiatry 2013; 170: 877-85. IF 13.559
204. **Weißflog L, Scholz CJ, Jacob CP, Nguyen TT, Zamzow K, Groß-Lesch S,  
Renner TJ, Romanos M, Rujescu D, Walitza S, Kneitz S, Lesch KP, Reif A**  
KCNIP4 as a candidate gene for personality disorders and adult ADHD.  
Eur Neuropsychopharmacol 2013; 23: 436-447. IF 5.395
205. **Wenzel S, Pogarell O**  
Wichtige Ergänzung zur Rezidivprophylaxe und Trinkmengenreduktion.  
DNP Der Neurologe & Psychiater 2013; 14: 2-6. IF -
206. **Wobrock T, Falkai P, Schneider-Axmann T, Hasan A, Galderisi S,  
Davidson M, Kahn RS, Derks EM, Boter H, Rybakowski JK, Libiter J,  
Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Gaebel W, Fleischhacker  
WW, EUFEST study group**  
Comorbid substance abuse in first-episode schizophrenia: effects of cognition and  
psychopathology in the EUFEST study.  
Schizophr Res 2013; 147: 132-9. IF 4.426
207. **Wöstmann NM, Aichert DS, Costa A, Rubia K, Möller H-J, Ettinger U**  
Reliability and plasticity of response inhibition and interference control.  
Brain Cogn 2013; 81: 82-94. IF 2.683
208. **Zerwas S, Lund BC, Von Holle A, Thornton LM, Berrettini WH, Brandt H,  
Crawford S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, La Via M,  
Mitchell J, Rotondo A, Strober M, Woodside DB, Kaye WH, Bulik CM**  
Factors associated with recovery from anorexia nervosa.  
J Psychiatr Res 2013; 47: 972-979. IF 4.092
209. **Zorina OI, Haueis P, Greil W, Grohmann R, Kullak-Ublick GA, Russmann  
S**  
Comparative performance of two drug interaction screening programmes  
analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients.  
Drug Saf 2013; 36: 247-258. IF 2.620